KALV
NASDAQ · Biotechnology
Kalvista Pharmaceuticals Inc
$27.00
+0.01 (+0.04%)
Financial Highlights (FY 2026)
Revenue
48.50M
Net Income
-108,244,051
Gross Margin
93.7%
Profit Margin
-223.2%
Rev Growth
—
D/E Ratio
1.11
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.7% | 32.0% | 32.0% | 32.0% |
| Operating Margin | -228.3% | -32.2% | -31.2% | -31.4% |
| Profit Margin | -223.2% | -28.6% | -31.0% | -32.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 48.50M | 272.43M | 275.70M | 294.93M |
| Gross Profit | 45.46M | 87.18M | 88.23M | 94.38M |
| Operating Income | -110,721,390 | -87,704,275 | -85,953,547 | -92,707,107 |
| Net Income | -108,244,051 | -77,974,346 | -85,417,882 | -94,496,772 |
| Gross Margin | 93.7% | 32.0% | 32.0% | 32.0% |
| Operating Margin | -228.3% | -32.2% | -31.2% | -31.4% |
| Profit Margin | -223.2% | -28.6% | -31.0% | -32.0% |
| Rev Growth | — | +3.3% | +15.2% | -10.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 378.11M | 33.61M | 40.44M | 36.10M |
| Total Equity | 340.64M | 463.75M | 471.36M | 451.03M |
| D/E Ratio | 1.11 | 0.07 | 0.09 | 0.08 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -109,772,064 | -125,574,606 | -125,457,307 | -124,623,061 |
| Free Cash Flow | — | -59,177,907 | -68,220,346 | -69,677,831 |